Mesoblast Limited (FRA:LWB)

Market Cap	1.73B +55.7%
Revenue (ttm)	55.69M +1,053.2%
Net Income	-80.37M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	417.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	13
Open	1.288
Previous Close	1.292
Day's Range	1.287 - 1.288
52-Week Range	0.840 - 1.710
Beta	n/a
RSI	51.58
Earnings Date	May 25, 2026

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 81
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LWB

Financial Performance

In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Financial numbers in USD